BridgeMD
New treatment option for Microvascular Angina
Official title Microvascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS)
ClinicalTrials.gov ID: NCT06092736
What this study is testing
What is Compound Danshen Dropping Pills?
Compound Danshen Dropping Pills is an investigational medicine, given as an once-weekly infusion into a vein, being studied as a potential treatment for microvascular angina.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Coronary microvascular disease (MVD) refers to exertional angina or myocardial ischemia caused by abnormal structure and/or function of precoronary arterioles and arterioles under the action of various pathogenic factors. The symptoms of patients with coronary microvascular disease are mainly exertion-related chest pain episodes.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 75
You may be able to join if
- with typical symptoms of exertional angina;
- coronary CTA or angiography with normal coronary artery or \<50% stenosis, or \<50% residual coronary stenosis after revascularization;
- resting electrocardiogram or During exercise stress, it was found that the ST segment had an ischemic downward shift (the horizontal or downward...
- Transthoracic ultrasound examination of blood in the anterior descending coronary artery before and after intravenous injection of adenosine Flow...
- The patient himself agrees to participate in this study.
You likely can't join if
- Less than 30 years old or more than 75 years old;
- Have a history of carotid endarterectomy or stent implantation, and have a history of stroke;
- Myocarditis, pericardial disease, valvular disease, cardiomyopathy;
- Difficult to control diabetes mellitus (fasting blood glucose\>7.0 mmol/L);
- Uncontrolled hypertension (SBP\>150 mmHg and/or DBP\>90 mmHg);
- Familial hypercholesterolemia;
See the full eligibility criteria
- with typical symptoms of exertional angina;
- coronary CTA or angiography with normal coronary artery or \<50% stenosis, or \<50% residual coronary stenosis after revascularization;
- resting electrocardiogram or During exercise stress, it was found that the ST segment had an ischemic downward shift (the horizontal or downward slope after the J-point shift \> 0.1 mv, lasting 0.08 s);
- Transthoracic ultrasound examination of blood in the anterior descending coronary artery before and after intravenous injection of adenosine Flow reserve check CFR\<2.5;
- The patient himself agrees to participate in this study.
- Less than 30 years old or more than 75 years old;
- Have a history of carotid endarterectomy or stent implantation, and have a history of stroke;
- Myocarditis, pericardial disease, valvular disease, cardiomyopathy;
- Difficult to control diabetes mellitus (fasting blood glucose\>7.0 mmol/L);
- Uncontrolled hypertension (SBP\>150 mmHg and/or DBP\>90 mmHg);
- Familial hypercholesterolemia;
- Multiple Takayasu arteritis;
- Those who are pregnant or lactating, or have fertility intention within one year, or have not taken effective contraceptive measures during the childbearing period;
- Abnormal liver function (the level of serum GPT is 3.0 times higher than the upper limit of normal value) or abnormal renal function (the level of serum creatinine is more than 2 mg/dl);
- Other respiratory, digestive, blood, infection, immunity, endocrine, neuropsychiatric, tumor diseases with clinical significance that may cause serious danger to patients;
- Taking traditional Chinese medicine preparations of K channel opener, promoting blood circulation and removing blood stasis to improve microcirculation;
- Allergies to intra arterial injection of contrast agents, blood and blood products;
- Patients who are participating in other clinical studies.
The study team makes the final eligibility decision.
Where it's taking place
- Jinan, Shandong, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jinan, Shandong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.